VEEV stock forecast, quote, news & analysis
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry... Show more
Why Veeva Systems (VEEV) Stock Is Up +34% in the Last 30 Days
Key Takeaways
- Veeva Systems shares climbed roughly 34% over the trailing 30 days, from about $184.55 to $247.90, as of the most recent close.
- A major catalyst was Eli Lilly committing to Veeva Vault CRM globally, reinforcing Veeva's momentum with large pharmaceutical customers.
- The advance extends a broader rebound, with the stock up more than 50% over the past quarter.
- Veeva's fiscal second-quarter 2027 results, scheduled for late August, represent the next significant event for the shares.
- Wall Street retains a broadly Buy-leaning consensus, with average price targets near the low-to-mid $250s.
Veeva Systems (VEEV) Company Overview and Market Position
Veeva Systems is a cloud software and data provider built specifically for the global life sciences industry. Headquartered in Pleasanton, California, the company serves pharmaceutical, biotechnology, and medical device organizations across clinical, regulatory, quality, safety, and commercial operations. Its core products include the Veeva Vault suite for R&D and quality workflows, Veeva CRM and Vault CRM for commercial teams, and data and analytics offerings such as Veeva Data Cloud, Crossix, and Compass.
Veeva's competitive strength comes from the depth of its industry-specific software, which is embedded close to the operational core of its customers and supported by a highly recurring subscription revenue model. Investors follow the stock for its consistent double-digit revenue growth, disciplined profitability, and its expanding role in applying AI to regulated life-sciences workflows.
Veeva Systems (VEEV) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, VEEV shares advanced from a closing price of about $184.55 to $247.90, a gain of roughly 34%. The move was not a straight line: the stock briefly pulled back near $179.58 in late July before a sustained rally through August carried it to a recent intraday high above $253.
The 30-day gain is part of a longer uptrend. Over the past quarter, VEEV has risen from approximately $160 to $247.90, an increase of about 55%. That recovery followed a period of weakness in May and June, when the stock traded down toward the $150 level before finding support and rebounding sharply. Even after the run, shares remain below their 52-week high of roughly $310.
What Drove VEEV Stock Price in the Last 30 Days
Several verified developments supported the recent advance. The most notable was the announcement that Eli Lilly selected Veeva Vault CRM globally, a high-profile customer commitment that signaled continued competitive wins for Veeva in its CRM migration cycle. The news reinforced confidence in Veeva's ability to convert large pharmaceutical accounts onto its newer platform.
Analyst activity also lent support. In mid-August, RBC Capital maintained an Outperform rating with a $275 price target, reflecting a constructive view of execution and long-term growth. More broadly, the shares benefited from a favorable backdrop for enterprise and vertical software names and renewed investor enthusiasm for AI-enabled applications.
Finally, the stock rallied into its fiscal second-quarter earnings report, with investors positioning ahead of results and updated guidance. The combination of customer wins, positive analyst commentary, and AI sentiment helped sustain the move.
What Drove VEEV Stock Performance Over the Last Quarter
The quarterly advance traces back to Veeva's fiscal first-quarter 2027 results reported in early June, when revenue rose 16.3% year over year to $882.95 million and non-GAAP earnings per share of $2.24 exceeded consensus estimates. Management raised full-year guidance for revenue, operating income, and earnings, signaling durable demand across both commercial and R&D segments.
The AI narrative has been a central theme. Veeva has positioned its Falcon agentic platform and Vault AI as a new layer of automation for clinical, regulatory, and safety workflows, while integrating its Ostro acquisition to enhance engagement between biopharma companies, healthcare professionals, and patients. Meanwhile, CRM migration momentum continued, with more than 150 customers live on Vault CRM and a reported win rate above 80% for migrations. These factors combined to lift investor sentiment from the mid-year lows.
Trending AI Robots
For investors seeking a data-driven approach, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron operates hundreds of AI trading bots that trade thousands of tickers, but only top-performing and most relevant bots appear in this section. Each bot varies in strategy, timeframe, and performance metrics, giving traders a way to compare different automated approaches across the market. Exploring the page can help investors understand how AI-driven strategies are being applied to active trading.
VEEV Stock Forecast Drivers: What Investors Should Watch Next
The next key event is Veeva's fiscal second-quarter 2027 earnings report, where consensus estimates point to roughly $905 million in revenue and non-GAAP earnings per share near $2.22. Investors will watch subscription revenue growth, billings, and any updates to full-year guidance, as well as commentary on the pace of Vault CRM migrations and early AI adoption.
Beyond earnings, the planned early-adopter release of the Falcon agentic platform later in the year will be an important milestone for Veeva's AI strategy. Broader factors to monitor include life-sciences customer spending, competitive pressure in CRM and enterprise software, and macroeconomic conditions that influence software valuations. While the recent momentum is notable, the shares carry a premium valuation that leaves limited room for error if growth or AI monetization disappoints.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VEEV's RSI Indicator leaves overbought zone
The 10-day RSI Indicator for VEEV moved out of overbought territory on August 21, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
VEEV broke above its upper Bollinger Band on August 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on VEEV as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for VEEV just turned positive on July 29, 2026. Looking at past instances where VEEV's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 190 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.525) is normal, around the industry mean (7.507). P/E Ratio (44.053) is within average values for comparable stocks, (46.636). Projected Growth (PEG Ratio) (1.114) is also within normal values, averaging (1.723). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (12.500) is also within normal values, averaging (6.337).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry